On October 15, 2025, MoonLake Immunotherapeutics was sued for violations of the federal securities laws in the United States District Court for the Southern District of New York on behalf of investors who purchased or otherwise acquired Defendant MoonLake Immunotherapeutics (“MoonLake” or the “Company”) common stock between March 10, 2024 through September 29, 2025, inclusive (the “Class Period”).
We use cookies to improve your overall web experience. By using our website, you consent to the use of cookies in accordance with our Privacy Policy.